1. Home
  2. ENTX vs SCWO Comparison

ENTX vs SCWO Comparison

Compare ENTX & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SCWO
  • Stock Information
  • Founded
  • ENTX 2010
  • SCWO 2021
  • Country
  • ENTX Israel
  • SCWO United States
  • Employees
  • ENTX N/A
  • SCWO N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SCWO Environmental Services
  • Sector
  • ENTX Health Care
  • SCWO Utilities
  • Exchange
  • ENTX Nasdaq
  • SCWO Nasdaq
  • Market Cap
  • ENTX 104.0M
  • SCWO 56.4M
  • IPO Year
  • ENTX 2018
  • SCWO N/A
  • Fundamental
  • Price
  • ENTX $1.72
  • SCWO $0.19
  • Analyst Decision
  • ENTX Strong Buy
  • SCWO
  • Analyst Count
  • ENTX 1
  • SCWO 0
  • Target Price
  • ENTX $10.00
  • SCWO N/A
  • AVG Volume (30 Days)
  • ENTX 36.8K
  • SCWO 1.4M
  • Earning Date
  • ENTX 08-08-2025
  • SCWO 08-13-2025
  • Dividend Yield
  • ENTX N/A
  • SCWO N/A
  • EPS Growth
  • ENTX N/A
  • SCWO N/A
  • EPS
  • ENTX N/A
  • SCWO N/A
  • Revenue
  • ENTX $223,000.00
  • SCWO $673,267.00
  • Revenue This Year
  • ENTX N/A
  • SCWO $5,945.19
  • Revenue Next Year
  • ENTX N/A
  • SCWO $106.82
  • P/E Ratio
  • ENTX N/A
  • SCWO N/A
  • Revenue Growth
  • ENTX N/A
  • SCWO 161.19
  • 52 Week Low
  • ENTX $1.41
  • SCWO $0.16
  • 52 Week High
  • ENTX $2.79
  • SCWO $1.99
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 35.45
  • SCWO 34.92
  • Support Level
  • ENTX $1.75
  • SCWO $0.16
  • Resistance Level
  • ENTX $1.88
  • SCWO $0.44
  • Average True Range (ATR)
  • ENTX 0.11
  • SCWO 0.05
  • MACD
  • ENTX -0.02
  • SCWO -0.02
  • Stochastic Oscillator
  • ENTX 0.00
  • SCWO 15.11

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

Share on Social Networks: